Popular terms

Autoimmune topics
Autoimmune
Immune Disease
Autoimmune Disease
Immune Diseases
Autoimmune Diseases
Transplant
Immune Disorder
Autoimmune Disorder
Autoimmune Disorders
Infectious
Infectious Disease
Inflammatory Disease
Type 1 Diabetes
Proliferative Disorder
Recurrence

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Autoimmune patents



      
           
This page is updated frequently with new Autoimmune-related patent applications.



Date/App# patent app List of recent Autoimmune-related patents
01/28/16
20160025726 
 Methods for detecting peptide/mhc/tcr binding patent thumbnailMethods for detecting peptide/mhc/tcr binding
Provided herein are compositions and methods for detecting the binding of a peptide to an mhc molecule, and the binding of a peptide: mhc complex to a tcr. In preferred embodiments, the compositions and methods are in a highly-multiplexed way.
Prognosys Biosciences, Inc.


01/28/16
20160024508 
 Method for identifying biologically active oligonucleotides capable of modulating the immune system patent thumbnailMethod for identifying biologically active oligonucleotides capable of modulating the immune system
The present invention relates to methods of identifying oligonucleotides capable of modulating the immune system in a mammalian subject, comprising analysis of which tertiary structural type said oligonucleotide adopts, in phosphate-buffered saline solution. Further, the invention provides oligonucleotides identifiable by the methods of the invention and to their use in methods of treating diseases, such as inflammatory diseases, autoimmune diseases, infectious diseases, neurodegenerative diseases and cancer..
Index Pharmaceuticals Ab


01/28/16
20160024220 
 Pharmaceutical composition comprising an anti-cd6 monoclonal antibody used in the diagnosis and treatment of rheumatoid arthritis patent thumbnailPharmaceutical composition comprising an anti-cd6 monoclonal antibody used in the diagnosis and treatment of rheumatoid arthritis
The present invention is related to the branch of immunology and particularly with the generation of pharmaceutical compositions containing a humanized monoclonal antibody recognizing the leukocyte differentiation antigen cd6. Accordingly with that statement, the purpose of this invention is to provide pharmaceutical compositions which contain a humanized anti-cd6 monoclonal antibody for the diagnosis and treatment of autoimmune diseases, particularly the rheumatoid arthritis..
Centro De Inmunologia Molecular


01/28/16
20160024219 
 Anti-cd52 antibodies patent thumbnailAnti-cd52 antibodies
Anti-human cd52 antibodies and antigen-binding fragments thereof are provided. Also provided are isolated nucleic acids, recombinant vectors and host cells for making the antibodies and fragments.
Genzyme Corporation


01/28/16
20160024215 
 Llt-1 antibodies with new functional properties patent thumbnailLlt-1 antibodies with new functional properties
The present invention relates to monoclonal antibodies that are capable of specifically binding to lectin-like transcript 1 (llt1), to polynucleotides encoding such antibodies, and to cells that express such antibodies. Antibodies of the invention have utility in the treatment of autoimmune diseases and cancer, in which llt1- and cd161-expressing cells play a role in disease pathogenesis..
Centre National De La Recherche Scientifique


01/28/16
20160024212 
 Humanized anti-hla-dr antibodies patent thumbnailHumanized anti-hla-dr antibodies
The present invention concerns compositions and methods of use of humanized anti-hla-dr antibodies. In preferred embodiments, the antibodies induce apoptosis and inhibit proliferation of lymphoma cells without inducing cdc or adcc.
Immunomedics, Inc.


01/28/16
20160024211 
 Methods of modulating immune function patent thumbnailMethods of modulating immune function
Presented herein are therapeutic agents that modulate one or more immune functions and uses of such therapeutic agents in the prevention, treatment and management of diseases. In one aspect, the therapeutic agents modulate one or more signal transduction pathways induced by the binding of b7-h7 to b7-hrcr, or the binding of b7-h2 to either icos, cd28, or ctla-4.
The Johns Hopkins University


01/28/16
20160024183 
 Synthetic peptides for the treatment of autoimmune diseases patent thumbnailSynthetic peptides for the treatment of autoimmune diseases
The present invention provides synthetic peptides, including peptides comprising a plurality of epitopes, each epitope being derived from a different protein, and peptides comprising a plurality of citrullinated residues. The present invention also related to use of said peptides for the treatment of autoimmune diseases and disorder..
Tel Hashomer Medical Research Infrastructure And Services Ltd.


01/28/16
20160024109 
 Tricyclic fused thiophene derivatives as jak inhibitors patent thumbnailTricyclic fused thiophene derivatives as jak inhibitors
The present invention provides tricyclic fused thiophene derivatives, as well as their compositions and methods of use, that modulate the activity of janus kinase (jak) and are useful in the treatment of diseases related to the activity of jak including, for example, inflammatory disorders, autoimmune disorders, cancer, and other diseases.. .
Incyte Holdings Corporation


01/28/16
20160022793 
 Compositions for treatment and/or prevention of autoimmune disorders patent thumbnailCompositions for treatment and/or prevention of autoimmune disorders
The invention provides compositions for treating or preventing t1d (t1d), the compositions comprising one or more antigen presenting cells (apc) that have been pulsed with one or more bacteria and/or components of the bacteria, wherein the bacteria or their components confer upon the apcs the ability to inhibit the generation of diabetes-promoting t cells. The subject invention also provides a method of treating or preventing t1d in a subject, the method comprising administering apc that have been pulsed with one or more bacteria and/or components of the bacteria and wherein the bacteria or their components confer upon the apcs the ability to inhibit the generation of diabetes-promoting t cells..
University Of Florida Research Foundation, Inc.


01/28/16
20160022788 

Compositions and methods for treating autoimmune diseases


The present invention provides compositions comprising immunologically effective amounts of one or more autoimmune disease associated antigens or antigenic fragments or derivatives thereof and one or more th2 promoting adjuvants. The compositions may optionally comprise one or more th2 promoting tlr2 ligands.
Albany Medical College


01/28/16
20160022767 

Protein particles comprising disulfide crosslinkers and uses


This disclosure relates to particles comprising recombinant proteins, pharmaceutical composition comprising the particles, and therapeutic uses related thereto. In certain embodiments, the particles are made by the process of producing recombinant proteins and conjugating the recombinant proteins to form nanoparticles with a linking reagent comprising disulfide bonds.
Emory University


01/28/16
20160022759 

Methods for increasing the selective efficacy of gene therapy using car peptide and heparan-sulfate mediated macropinocytosis


Disclosed are compositions and methods for triggering disease selective macropinocytosis. The compositions can serve as a marker of disease activity and as a trigger of enhanced macropinocytosis in tissues undergoing disease remodeling such as wound healing, cancer, pah, inflammation, diabetes, crohn's disease, ulcerative colitis, ankylosing spondylitis, diseases of the endometrium, psoriasis, irritable bowel syndrome, arthritis, fibrotic disorders, interstitial cystitis, autoimmune diseases, asthma, acute lung injury, and adult respiratory distress syndrome.
Vascular Biosciences


01/28/16
20160022704 

Fluocinolone formulations in a biodegradable polymer carrier


Effective treatments of pain and inflammation are provided. Through the administration of an effective amount of fluocinolone at or near a target site, one can reduce, prevent or treat inflammation and pain and autoimmune disorders.
Medtronic, Inc.


01/28/16
20160022702 

Methods for treating inflammation, autoimmune disorders and pain


Methods of treating, reducing, or preventing a disease or symptom relating to a disease such as oral mucositis, gingivitis, periodontitis, gastric mucositis, inflammatory fibrosis, gastritis, colitis, ileitis, crohn's disease, chronic inflammatory intestinal disease, inflammatory bowel syndrome, chronic inflammatory bowel disease, celiac disease, ulcerative colitis, a gastric ulcer, a peptic ulcer, a buccal ulcer, a nasopharyngeal ulcer, an esophageal ulcer, a duodenal ulcer, a gastrointestinal ulcer, an autoimmune disorder, inflammation associated with cancer, cancer treatment, or radiation, and/or pain that include: identifying a patient in need of treatment; and administering a therapeutically effective amount of at least one cationic steroid antimicrobial (csa), or a pharmaceutically acceptable salt thereof. Kits comprising such compositions and instructions on such methods are also contemplated herein..

01/28/16
20160022683 

Combinations of bruton's tyrosine kinase inhibitors and cyp3a4 inhibitors


Combinations of bruton's tyrosine kinase (btk) inhibitors, e.g., 1-((r)-3-(4-amino-3-(4-phenoxyphenyl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, with cyp3a4 inhibitors are provided. Also provided are methods of treating cancers, and autoimmune disorders by administering combinations of bruton's tyrosine kinase (btk) inhibitors, e.g., 1-4((r)-3-(4-amino-3-(4-phenoxyphenyl)-1 h-pyrazolo[3, 4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, and cyp3a4 inhibitors..
Pharmacyclics Llc


01/28/16
20160022640 

Pyrazole derivatives and their uses thereof


The present disclosure relates to a compound of formula (i) or a pharmaceutically acceptable salt thereof; wherein u, r1, r2, r3 and q are as defined herein. The disclosure also provides a method for treating or preventing a method for the prevention, treatment and/or alleviation of one or more autoimmune or alloimmune disease, pharmaceutical compositions and combination comprising a therapeutically effective amount of a compound, as defined herein..
University Health Network


01/28/16
20160022476 

Methods and therapeutic application of thermal energy including blood viscosity adjustment


Apparatus and methods are provided for treating a human condition by providing an appendage chamber having a thermal exchange member. Negative pressure may be applied to a human appendage when placed within the appendage chamber.
Avacen, Inc.


01/21/16
20160018407 

Metabolic profiles


The invention relates to the use of endogenous metabolites to produce a metabolic profile of a disorder or disease in a subject, e.g. An autoimmune disease, in particular rheumatoid arthritis, and the analysis of such metabolic profiles in order to find disturbances in such profiles in a subject which are caused by or correlated with the said diseases or disorders.
Anamar Ab


01/21/16
20160017428 

Recombination sequence (rs) rearrangement frequency as a measure of central b cell tolerance


The invention relates to methods and materials for diagnosing an autoimmune disease such as sle, type 1 diabetes, and the like. More particularly, the invention relates to methods and materials for assessing the frequency of recombination sequence (rs) rearrangement as a novel marker for an autoimmune disease.
The Trustees Of The University Of Pennsylvania


01/21/16
20160017058 

Bispecific antibodies and uses thereof


Methods, compositions and uses are provided for bispecific antibodies comprising one or more unnatural amino acids. The bispecific antibodies may bind to two or more different receptors, co-receptors, antigens, or cell markers on one or more cells.
The Scripps Research Institute


01/21/16
20160017024 

Fam150a, fam150b, and fam150 antagonists and uses thereof


Methods of identifying and using fam150a agents, fam150b agents, and fam150 antagonists are provided. Methods of identifying and using ltk agonists (including ltk agonist antibodies, fam150a agents, and fam150b agents) and fam150 antagonists are provided.
Five Prime Therapeutics, Inc.


01/21/16
20160016981 

Amino- or ammonium-containing sulfonic acid, phosphonic acid and carboxylic acid derivatives and their medical use


The present invention relates to amino- or ammonium-containing sulfonic acid, phosphonic acid and carboxylic acid derivatives, in particular the compounds of formula 1, 2, 3, 4, 5 or 6, and their medical use, including their use in the treatment, prevention or amelioration of an inflammatory, autoimmune and/or allergic disorder.. .
Glycoregimmune, Inc.


01/21/16
20160016946 

Methods, compounds, and compositions for the treatment of angiotensin-related diseases


Disclosed are small molecule non-peptidic compounds, as well as methods and compositions for the treatment of angiotensin-related diseases and disorders, including cardiovascular diseases, metabolic diseases, gastrointestinal diseases, renal diseases, inflammatory/autoimmune diseases, neurological diseases, bone marrow diseases and cancer.. .
University Of Southern California


01/21/16
20160016914 

Spirocycloheptanes as inhibitors of rock


Or stereoisomers, tautomers, or pharmaceutically-acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective rock inhibitors.

01/21/16
20160016910 

Phenylpyrazole derivatives as potent rock1 and rock2 inhibitors


The present invention provides compounds of formula (i): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective rock inhibitors.
Bristol-meyers Squibb Company


01/21/16
20160016904 

Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof


The present invention relates to processes and intermediates useful in the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid of formula (i) and salts thereof, an s1p1 receptor modulator that is useful in the treatment of s1p1 receptor-associated disorders, for example, diseases and disorders mediated by lymphocytes, transplant rejection, autoimmune diseases and disorders, inflammatory diseases and disorders (e.g., acute and chronic inflammatory conditions), cancer, and conditions characterized by an underlying defect in vascular integrity or that are associated with angiogenesis such as may be pathologic (e.g., as may occur in inflammation, tumor development and atherosclerosis).. .
Arena Pharmaceuticals, Inc.


01/21/16
20160015821 

Glycotargeting therapeutics


Glycotargeting therapeutics are useful in the treatment of transplant rejection, autoimmune disease, food allergy, and immune response against a therapeutic agent.. .
Anokion Sa


01/21/16
20160015751 

Method for enhancing a function of a t cell


Disclosed is a method for enhancing the function of a t cell, which is characterized by inhibiting the expression of programmed death-1 ligand 1 (pd-l1) and/or programmed death-1 ligand 2 (pd-l2) in the t cell. Also disclosed is a function-enhanced t cell which is produced by the function enhancement method.
Takara Bio Inc.


01/21/16
20160015729 

Glycan-based drugs, therapies and biomarkers


The present disclosure discloses simple and efficient glycan- or carbohydrate-based processes or methods for the rapid identification of biological markers and therapeutic targets especially glycan-related targets of infectious diseases, cancers, autoimmune diseases, allergies, inflammation, toxicity, obesity and/or other disorders of humans, animals, plants and other organisms. Therefore, novel methods and products for the diagnosis, prevention, and treatment of such diseases obtainable based on these therapeutic targets can be developed..

01/21/16
20160015714 

Use of a dpp-4 inhibitor in autoimmune diabetes, particularly lada


The present invention relates to methods for treating and/or preventing autoimmune diabetes, particularly lada, as well as diseases related or associated therewith, comprising the administration of an effective amount of a certain dpp-4 inhibitor, as well as to the use of a certain dpp-4 inhibitor for modifying disease trajectory of autoimmune diabetes (particularly lada).. .
Boehringer Ingelheim International Gmbh


01/21/16
20160015695 

Tricyclic fused thiophene derivatives as jak inhibitors


The present invention provides tricyclic fused thiophene derivatives, as well as their compositions and methods of use, that modulate the activity of janus kinase (jak) and are useful in the treatment of diseases related to the activity of jak including, for example, inflammatory disorders, autoimmune disorders, cancer, and other diseases.. .
Incyte Holdings Corporation


01/14/16
20160009803 

Therapeutic methods using anti-cd200 antibodies


The present disclosure relates to anti-cd200 antibodies and to use of the antibodies in methods for treating autoimmune disorders and cancer. Also featured are biomarkers for use in selecting or prescribing a treatment modality for a patient with an autoimmune disorder and/or cancer.
Alexion Pharmaceuticals, Inc.


01/14/16
20160009730 

Hdac6 inhibitors and uses thereof


Histone deacetylases 6 (hdac6) inhibitors and compositions containing the same. Methods of treating diseases and conditions wherein inhibition of hdac6 provides a benefit, like a cell proliferative disease, an autoimmune or inflammatory disorder, a neurodegenerative disease, a viral disease, malaria, or a combination thereof..

01/14/16
20160009725 

Pyrrolo- and pyrazolo-triazolodiazepines as bet-protein inhibitors for treating hyperproliferative diseases


In which x, y, n, m, r1, r2, r3, r4 and r5 are each as defined in the description, to intermediates for preparation of the inventive compounds, to pharmaceutical compositions comprising the inventive compounds, and to the prophylactic and therapeutic use thereof for hyperproliferative disorders, especially for tumour disorders. Also described is the use of the compounds according to the invention as bet protein inhibitors for benign hyperplasias, for atherosclerotic disorders, for sepsis, for autoimmune disorders, for vascular disorders, for viral infections, for neurodegenerative disorders, for inflammatory disorders, for atherosclerotic disorders and for male fertility control..

01/14/16
20160008608 

Implantable neurostimulator with integral hermetic electronic enclosure, circuit substrate, monolithic feed-through, lead assembly and anchoring mechanism


An implantable medical device is provided for the suppression or prevention of pain, movement disorders, epilepsy, cerebrovascular diseases, autoimmune diseases, sleep disorders, autonomic disorders, abnormal metabolic states, disorders of the muscular system, and neuropsychiatric disorders in a patient. The implantable medical device can be a neurostimulator configured to be implanted on or near a cranial nerve to treat headache or other neurological disorders.

01/14/16
20160008463 

Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns


A pharmaceutical composition comprising an active agent that causes reduction of the level of systemic immunosuppression in an individual for use in treating a disease, disorder, condition or injury of the cns that does not include the autoimmune neuroinflammatory disease, relapsing-remitting multiple sclerosis (rrms), is provided. The pharmaceutical composition is for administration by a dosage regimen comprising at least two courses of therapy, each course of therapy comprising in sequence a treatment session followed by an interval session of non-treatment..
Yeda Research And Development Co. Ltd


01/14/16
20160008440 

Use of cd83 in combination therapies


The present invention relates to improved methods of suppressing and/or preventing an undesired immune response comprising the use of cd83. In some embodiments, cd83 is coadministered to a subject with at least one other immunosuppressive compound.
Argos Therapeutics, Inc.


01/14/16
20160008397 

Immunomodulation by controlling expression levels of micrornas in dendritic cells


Compositions and methods of modulating an immune response by controlling expression levels of micrornas in dendritic cells are disclosed. In particular, the invention relates to modified dendritic cells and methods of using such dendritic cells in cellular therapy for treating various immune conditions and diseases, including transplant rejection, inflammatory disorders, autoimmune diseases, allergies, infectious diseases, immunodeficiency, and cancer..
The Board Of Trustees Of The Leland Stanford Junior University


01/14/16
20160008377 

Formulations and compositions of vitamin d analogs for treating and preventing cancer and other diseases


This invention is for formulations of analogs of the non-toxic and inert vitamin d3, its non-toxic and mostly inert pre-hormone and its toxic and biologically active hormone, and for using these formulations for preventing and treating certain cancers such as breast, prostate, ovarian, kidney, renal and other cancers, vitamin d deficiency, autoimmune disease such as multiple sclerosis, hypertension, osteoporosis, bone diseases, rickets, psoriasis and infectious diseases. This invention also discloses compositions of the analogs of the non-toxic and inert vitamin d3 and the non-toxic and mostly inert vitamin d3 pre-hormone..
Aphios Corporation


01/07/16
20160002337 

Hhla2 as a novel inhibitor of human immune system and uses thereof


Provided are methods of treating an autoimmune disease in a subject, or of suppressing transplant rejection in a subject, or of treating a cancer in a subject, as well as compositions therefor.. .
Albert Einstein College Of Medicine Of Yeshiva University


01/07/16
20160002336 

Methods of modulating immune function


Presented herein are therapeutic agents that modulate one or more immune functions and uses of such therapeutic agents in the prevention, treatment and management of diseases. In one aspect, the therapeutic agents modulate one or more signal transduction pathways induced by the binding of b7-h7 to b7-hrcr, or the binding of b7-h2 to either icos, cd28, or ctla-4.
The Johns Hopkins University


01/07/16
20160002335 

Therapeutic use of anti-cs1 antibodies


The present invention is directed to antagonists of cs1 that bind to and neutralize at least one biological activity of cs1. The invention also includes a pharmaceutical composition comprising such antibodies or antigen-binding fragments thereof.
Abbvie Biotherapeutics Inc.


01/07/16
20160002241 

Inhibitors of bruton's tyrosine kinase


Disclosed herein are compounds that form covalent bonds with bruton's tyrosine kinase (btk). Also described are irreversible inhibitors of btk.
Pharmacyclics, Llc.


01/07/16
20160002232 

Substituted n-(1h-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as type iii receptor tyrosine kinase inhibitors


Compounds useful in the treatment of fibrosis, bone-related diseases, cancer, autoimmune disorders, inflammatory diseases, cardiovascular diseases, pain and burns in a mammal.. .
Array Biopharma Inc.


01/07/16
20160002225 

Inhibitors of bruton's tyrosine kinase


Disclosed herein are compounds that inhibit bruton's tyrosine kinase (btk). Also described are irreversible inhibitors of btk.

01/07/16
20160002187 

Apoptosis-inducing agent for the treatment of cancer and immune and autoimmune diseases


Disclosed are compounds which inhibit the activity of anti-apoptotic bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic bcl-2 protein.. .
Abbvie Inc.


01/07/16
20160002172 

Phenylpyrazole derivatives as potent rock1 and rock2 inhibitors


The present invention provides compounds of formula (i): (i) or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective rock inhibitors.
Bristol-myers Squibb Company




Autoimmune topics: Autoimmune, Immune Disease, Autoimmune Disease, Immune Diseases, Autoimmune Diseases, Transplant, Immune Disorder, Autoimmune Disorder, Autoimmune Disorders, Infectious, Infectious Disease, Inflammatory Disease, Type 1 Diabetes, Proliferative Disorder, Recurrence

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Autoimmune for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Autoimmune with additional patents listed. Browse our RSS directory or Search for other possible listings.


0.7979

5888

1 - 1 - 115